These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 13383105)

  • 21. The significance of abnormal preoperative hemostatic tests.
    Bowie EJ; Owen CA
    Prog Hemost Thromb; 1980; 5():179-209. PubMed ID: 6775346
    [No Abstract]   [Full Text] [Related]  

  • 22. Studies on factor VIII activation potential in hemophilia A-plasma and its significance for the comprehension of hemophilia.
    Mingers AM
    Eur J Pediatr; 1976 Oct; 123(3):187-98. PubMed ID: 1086208
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Canine von Willebrand's disease.
    Dodds WJ
    J Lab Clin Med; 1970 Nov; 76(5):713-21. PubMed ID: 5312238
    [No Abstract]   [Full Text] [Related]  

  • 24. Antihaemophilic-factor-like protein in haemophilia.
    Ekert H; Helliger H; Muntz RH
    Med J Aust; 1973 Aug; 2(5):210-2. PubMed ID: 4542740
    [No Abstract]   [Full Text] [Related]  

  • 25. Letter: Enhanced factor VIII activity in von Willebrand's disease.
    Mannucci PM; Pareti FI; Ruggeri ZM
    N Engl J Med; 1974 May; 290(22):1259. PubMed ID: 4545219
    [No Abstract]   [Full Text] [Related]  

  • 26. [The so-called prothrombin consumption test in hemophilia (in the male and the carrier) and in Willebrand-Jergens constitutional thrombopathy].
    JURGENS R; FERLIN A
    Schweiz Med Wochenschr; 1950 Oct; 80(41):1098-101. PubMed ID: 14787382
    [No Abstract]   [Full Text] [Related]  

  • 27. [Factor VIII (anti-hemophilic A factor). Biology, physiology, pathology and genetics].
    Meyer D; Dray L; Allain JP; Larrieu MJ
    Pathol Biol (Paris); 1972; 20(11):607-23. PubMed ID: 4558579
    [No Abstract]   [Full Text] [Related]  

  • 28. Can we prevent inhibitors in mild and moderate factor VIII-deficient patients?
    Aledort LM
    J Thromb Haemost; 2006 Apr; 4(4):914. PubMed ID: 16634770
    [No Abstract]   [Full Text] [Related]  

  • 29. [Laboratory diagnosis of hemophilias].
    Egli H
    Dtsch Med J; 1968 Jul; 19(14):495-9. PubMed ID: 5305712
    [No Abstract]   [Full Text] [Related]  

  • 30. A 1973 look at hemophilia and von Willebrand's disease.
    Ratnoff OD
    Proc Inst Med Chic; 1973; 29(9):296-304. PubMed ID: 4581203
    [No Abstract]   [Full Text] [Related]  

  • 31. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
    CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A quantitative and humane tail bleeding assay for efficacy evaluation of antihaemophilic factors in haemophilia A mice.
    Molina ES; Fujita A; Sogayar MC; Demasi MA
    Haemophilia; 2014 Nov; 20(6):e392-8. PubMed ID: 24975823
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The immunological properties of factor VIII. I. Studies on the inhibitory activity of specific antisera to human antihemophilic globulin.
    Uszyński L
    Thromb Diath Haemorrh; 1966 Dec; 16(3):558-73. PubMed ID: 5301276
    [No Abstract]   [Full Text] [Related]  

  • 34. [The factor VIII complex: hemophilia A and von Willebrand disease].
    Tobelem G; Rothschild C
    Sem Hop; 1982 Sep; 58(35):2032-6. PubMed ID: 6293093
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Letter: Treatment of inhibitors to factor VIII with activated prothrombin concentrate.
    Sultan Y; Brouet JC; Debre P
    N Engl J Med; 1974 Nov; 291(20):1087. PubMed ID: 4414451
    [No Abstract]   [Full Text] [Related]  

  • 36. Low-molecular-weight factor VIII.
    Bloom AL; Giddings JC; Peake IR
    Lancet; 1973 Mar; 1(7804):661-2. PubMed ID: 4121859
    [No Abstract]   [Full Text] [Related]  

  • 37. Artificial factor VIII deficient plasma: preparation using monoclonal antibodies and its use in one stage coagulation assays.
    Hornsey VS; Waterston YG; Prowse CV
    J Clin Pathol; 1988 May; 41(5):562-7. PubMed ID: 3133400
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Capacity of activation of so-called deficient factors in hereditary blood coagulation disorders].
    Mingers AM
    Fortschr Med; 1976 Oct; 94(30):1723-5. PubMed ID: 1086815
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Pathogenesis and treatment of Willebrand's disease].
    Meili EO; Straub PW; Frick PG
    Schweiz Med Wochenschr; 1969 Dec; 99(50):1805-10. PubMed ID: 5311783
    [No Abstract]   [Full Text] [Related]  

  • 40. The type of factor VIII deficient plasma used influences the performance of the Nijmegen modification of the Bethesda assay for factor VIII inhibitors.
    Verbruggen B; Giles A; Samis J; Verbeek K; Mensink E; Novákovà I
    Thromb Haemost; 2001 Dec; 86(6):1435-9. PubMed ID: 11776311
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.